The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $713,689 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The three-year grant, effective September 1, 2023, will support UT Southwestern's research to leverage biophysicochemical motifs in T-cell receptor antigen binding regions and antigen co-occurrence to predict response to immune checkpoint inhibitors. The grant provides funding for basic...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $1,486,400 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports a 4-year research project titled "STRUCTURAL DIAGNOSIS OF TAUOPATHIES" with a period of performance from June 15, 2024 to June 14, 2028. Through this grant, UT Southwestern will conduct innovative biomedical research on tauopathies, a class of...
The University of Texas Southwestern Medical Center was awarded a $1,639,837 Project Grant under the Military Medical Research and Development program (CFDA 12.420) by the Defense Health Agency. The 4-year grant, awarded on June 15, 2024, supports a research project titled "STRUCTURAL DIAGNOSIS OF TAUOPATHIES" focused on advancing the diagnosis and treatment of neurodegenerative tauopathies. As a leading academic medical center, UT Southwestern will leverage its expertise in biomedical...
This federal Project Grant award in the amount of $617,537 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award, with a performance period from September 1, 2024 to August 31, 2027, supports research conducted by The University of Texas Southwestern Medical Center (UT Southwestern) to examine heterogeneity in response to disease-modifying therapy for multiple sclerosis. As a prominent academic medical center, UT...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $766,965 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) on June 30, 2024. The grant supports a 3-year research project to develop new methods for targeting kidney cancer tumors in order to improve immunotherapy outcomes. The research aims to identify tumor surface biomarkers that can be leveraged to enhance the effectiveness of cancer...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $1,083,136 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from August 15, 2023 through August 14, 2026 to leverage SCARB1 overexpression for the treatment of clear cell renal cell carcinoma (CCRCC) using low-density lipoprotein nanocarriers. UT Southwestern has extensive experience delivering...
The University of Texas Southwestern Medical Center was awarded a $984,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Ribosome Marylation and Stress Responses in Ovarian Cancer: New Therapeutic Opportunities". The 3-year grant, effective September 1, 2024, will support basic science, translational, and clinical research to investigate new treatment approaches for ovarian cancer. As a...
The University of Texas Southwestern Medical Center (UT Southwestern) was awarded a $319,798 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) on April 15, 2024. The grant supports UT Southwestern's research to dissect unconventional mechanisms of action and resistance to rapalogs, a class of drugs, in renal cell carcinoma. The research aims to make significant advances in military medicine by improving...
The University of Texas Southwestern Medical Center (UT Southwestern) has been awarded a Project Grant for $1,180,962.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 30, 2024, will support a research project titled "TUMOR SURFACE BIOMARKER-INDEPENDENT TARGETING OF KIDNEY CANCER TO IMPROVE IMMUNOTHERAPY" over a performance period ending on June 29, 2027. The grant funding will enable UT...
The Defense Health Agency awarded a $1.1 million project grant to the University of Texas Southwestern Medical Center in Dallas, Texas, to support research under the Military Medical Research and Development program. The three-year award beginning in June 2023 will fund the development of a multifunctional immunotherapy nanoparticle to enable innate immunotherapy for kidney cancer. As the prime awardee, UT Southwestern will leverage its expertise in oncology and immunology to advance this...